Anal Squamous Cell Carcinoma (1)

Castrate Resistant Prostate Cancer (1)

Colorectal Neoplasms (1)

Gastroenteropancreatic Neuroendocrine Neoplasm (1)

Malignant Pleural Mesothelioma (1)

Neuroendocrine Carcinoma of Prostate (1)

Small Cell Lung Carcinoma (1)

Soft Tissue Sarcoma (1)

Not yet recruiting (1)

phase 2 (1)

Translational Research in Oncology (1)

Bayer (1)

Novartis (1)

regorafenib in combination with tislelizumab (1)

combination product (1)

Other (1)

Interventional (1)

neuroendocrine carcinoma of prostate

Showing 1 - 1 of 1

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Not yet recruiting

Oct 12, 2022